ACADIA Pharmaceuticals Inc. vs Vanguard S&P 500 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while Vanguard S&P 500 ETF trades at $709.86. Which is the better fit depends on your goals.
| ACAD | VOO | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.41 | $710.71 |
52-Week Low | $20.06 | $580.93 |
Enterprise Value | $4.19B | — |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →